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Summary box
What is already known about this subject?
 ► Symptom-based referral guidelines are poor predic-
tors of underlying significant bowel disease (SBD) in 
patients presenting to primary care.
 ► Previous studies have reported that a quantitative 
faecal immunochemical test (FIT) for faecal haemo-
globin concentration (f-Hb) could be used in prima-
ry care as a ‘rule-out test’ to exclude SBD (cancer, 
higher risk adenoma, inflammatory bowel disease).
What are the new findings?
 ► FIT can be introduced into routine clinical practice 
in primary care as an adjunct to clinical assessment 
and full blood count.
 ► Record linkage to the Scottish Cancer Registry has 
confirmed that an f-Hb <10 µg Hb/g faeces, in the 
absence of iron deficient anaemia, rectal bleeding, 
a palpable mass or persistent diarrhoea, identifies 
patients with an extremely low risk of developing 
colorectal cancer.
 ► In those patients who attended for colonoscopy, the 
prevalence of SBD is related to f-Hb; 32.3% of those 
with f-Hb ≥10 µg/g had SBD rising to 54.0% in those 
with f-Hb >400 µg/g.
How might it impact on clinical practice in the 
foreseeable future?
 ► FIT should become integral to the assessment of all 
patients presenting to primary care with new bowel 
symptoms to objectively determine the risk of un-
derlying SBD.
AbSTrACT
Objective To determine whether a faecal 
immunochemical test (FIT) for faecal haemoglobin 
concentration (f-Hb) can be safely implemented in primary 
care as a rule-out test for significant bowel disease 
(SBD) (colorectal cancer (CRC), higher risk adenoma 
(HRA) and inflammatory bowel disease (IBD)) when used 
as an adjunct to the clinical assessment of new bowel 
symptoms.
Design Single-centre prospective cohort study of all 
patients who attended primary care and submitted a FIT in 
the first calendar year of the service beginning December 
2015. f-Hb was estimated using HM-JACKarc (Kyowa 
Medex) with a clinical cut-off of ≥10 µg Hb/g faeces. 
Incident cases of CRC were verified via anonymised record 
linkage to the Scottish Cancer Registry.
results 5422 patients submitted 5660 FIT specimens, 
of which 5372 were analysed (positivity: 21.9%). 2848 
patients were referred immediately to secondary care 
and three with f-Hb <10 µg/g presented acutely within 
days with obstructing CRC. 1447 completed colonoscopy 
in whom overall prevalence of SBD was 20.5% (95 CRC 
(6.6%), 133 HRA (9.2%) and 68 IBD (4.7%)); 6.6% in 
patients with f-Hb <10 µg/g vs 32.3% in patients with 
f-Hb ≥10 µg/g. One CRC was detected at CT colonoscopy. 
2521 patients were not immediately referred (95.3% had 
f-Hb <10 µg/g) of which four (0.2%) later developed CRC. 
Record linkage identified no additional CRC cases within a 
follow-up period of 23–35 months.
Conclusion In primary care, measurement of f-Hb, in 
conjunction with clinical assessment, can safely and 
objectively determine a patient’s risk of SBD.
IntroductIon
It is estimated that 10% of all routine 
primary care visits are for bowel disorders1 
but only a proportion of these are referred 
to secondary care. Referral guidelines from 
the National Institute for Health and Care 
Excellence (NICE) highlight symptoms and 
clinical features which may suggest serious 
bowel pathology, but concede that symptoms 
have a positive predictive value for colorectal 
cancer (CRC) of only 3%–4%,2 as also docu-
mented in a review and meta-analysis.3 Some 
patients may be at risk of false reassurance; a 
recent UK National Cancer Diagnosis Audit 
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reported that only 41% of patients ultimately diagnosed 
with colon cancer had been referred from primary care 
via rapid access straight-to-test suspected cancer path-
ways.4 For those who are referred, colonoscopy is the 
gold standard test to exclude significant bowel disease 
(SBD); namely CRC, higher risk adenoma (HRA, defined 
as ≥3 adenomas or any adenoma ≥1 cm)5 and inflamma-
tory bowel disease (IBD): low-risk adenomas (<1 cm) are 
excluded from this category.6 Drives to detect cancer early 
have resulted in increased demand for colonoscopy,7 
but only 6%–13% of patients referred for colonoscopy 
from primary care have SBD.8 Unnecessary colonoscopy 
carries associated risks and costs.
A number of studies have investigated the utility of quan-
titative faecal immunochemical tests (FIT) for haemo-
globin (Hb) to assist primary care in determining who 
may harbour SBD.8–15 FITs use antibodies to the globin 
moiety and are specific for intact human faecal Hb and its 
early degradation products.16 In a pilot study we explored 
the utility of a quantitative FIT, which examined faecal Hb 
concentrations (f-Hb) in samples taken in primary care 
at the point of referral in patients with new bowel symp-
toms8: f-Hb less than the limit of detection proved a good 
‘rule-out test’ for SBD. These findings were replicated in 
similar smaller studies which used qualitative FIT17 18 and 
in one study using quantitative FIT.14 A very recent study 
has advocated the use of quantitative FIT to rule in CRC 
in patients presenting with the low-risk symptoms detailed 
in NICE NG12.19 As a result of the wealth of evidence and 
to clarify the application of FIT, NICE has recently devel-
oped diagnostic guidance (DG30) on quantitative FIT 
in primary care to guide referral for CRC, but suggested 
further studies were required.20 To date, there have been 
no published reports that describe implementation of 
FIT into routine practice in primary care, nor any which 
report long-term follow-up of patients with new bowel 
symptoms assessed in this way.
NHS Tayside serves a population of around 400 000. 
Each individual has a unique 10-digit identifier, the 
Community Health Index (CHI), which is associated 
with their patient record. Each year approximately 4000 
patients are referred from primary care to secondary 
care for assessment of bowel symptoms via an electronic 
referral portal. This population has no access to guaiac 
faecal occult blood tests (gFOBT; out with the National 
Bowel Cancer Screening Programme) as they were with-
drawn from routine laboratory services around 14 years 
ago due to concerns around diagnostic accuracy.21 These 
patients may be referred to either the direct-to-test 
colorectal service or to gastroenterology, but each service 
may redirect to the other at the discretion of the vetting 
consultant gastroenterologists. We wished to determine 
the impact of introducing quantitative FIT into routine 
practice within primary care on the outcome of patients 
presenting with new bowel symptoms if those found 
to have low f-Hb were not routinely referred,8 on the 
proviso that the f-Hb result should not replace good clin-
ical acumen.
Methods
From December 2015, the gastroenterology and labo-
ratory services collaborated to provide a quantitative 
FIT service to primary care (GP) surgeries, comprising 
written information detailing the rationale for meas-
uring f-Hb, and FIT kits comprising one specimen 
collection device (Kyowa Medex, Tokyo, Japan) and a 
pictorial patient instruction sheet. If patients presented 
with new-onset bowel symptoms, general practitioners 
(Gps) were recommended to request f-Hb as an adjunct 
to history taking, as per the NICE NG12 guidelines in 
force at that time,2 not the updated in July 2017 version 
which included reference to DG30.20 In addition, a full 
blood count and renal function test were mandated as 
per standard clinical practice. This initiative had the full 
support of the GP Area Medical Committee. GP educa-
tion was provided via a lecture on FIT and the relevance 
of f-Hb at a Protected Learning Time event hosted by 
Primary Care and attended by all GP surgeries, and was 
complemented by an educational newsletter distributed 
at the launch of the service. Practice nurses distributed a 
FIT kit to each patient. Patients were instructed to collect 
a single sample of faeces and to return the FIT device 
immediately in person to the GP surgery and from here 
they were delivered to Blood Sciences, Ninewells Hospital 
and Medical School, Dundee, at ambient temperature 
via the GP surgery routine sample collection service (a 
daily courier service) and stored at 4°C prior to analysis 
to ensure f-Hb stability. Analysis was performed from 
Monday to Friday, therefore the vast majority of samples 
were analysed on the day of arrival and results reported 
electronically to the requesting GP to provide rapid result 
turnaround. f-Hb was measured using an HM-JACKarc 
(Kyowa Medex) with an analytical working range of 
7–400 µg Hb/g faeces. Samples with results above the 
upper analytical limit were not diluted and reassayed, but 
reported as ≥400 µg/g. Results with f-Hb ≥10 µg/g were 
defined as positive, exactly as recommended in NICE 
DG30.20 The reports also sign-posted Gps to the Gastro-
enterology website, which advised that f-Hb <10 µg/g, 
in the absence of iron deficiency anaemia (IDA), rectal 
bleeding, persistent diarrhoea, or a mass, would suggest 
that SBD was extremely unlikely. The gastroenterology 
and laboratory services sent quarterly newsletters to all 
GP surgery practice managers and Gps to reinforce the 
relevance of f-Hb, reminders to request FIT in all patients 
referred, and practical advice to ensure the correct label-
ling of completed FIT devices.
The laboratory is accredited by the UK Accreditation 
Service to ISO 15189 standards. Patients referred to 
endoscopy were investigated within 6 weeks of referral. 
The NHS Tayside endoscopy units participate in the 
accreditation scheme of the Joint Accreditation Group 
on GI Endoscopy. All findings were recorded on the 
endoscopy reporting system by the endoscopists. The 
diagnoses of CRC, HRA and IBD were confirmed by a 
gastrointestinal pathologist.
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Data on all FIT specimens received in the first year 
of the service were retrieved from the laboratory data-
base and manually linked using the CHI number with 
the Health Board’s electronic patient record to access 
comprehensive patient data including all correspon-
dence, laboratory results, referrals to secondary care, 
colonoscopy findings, hospital admissions and any 
subsequent attendance at the primary care out-of-hours 
(OOH) service. Finally, in December 2018, the Health 
Informatics Centre (HIC), University of Dundee, used 
the CHI number of all patients who had submitted an FIT 
test to the laboratory to perform a post hoc anonymised 
record linkage with the Scottish Cancer Registry to iden-
tify all incident cases of CRC (International Classification 
of Diseases (ICD) codes C18, C19, and C20). Caldicott 
Guardian and ethical approvals were in place to cover 
the record linkage performed by HIC. MedCalc statistical 
software (MedCalc Software, Mariakerke, Belgium) was 
used for all calculations.
results
From 7 December 2015 to 7 December 2016, a total of 
5422 patients submitted a total of 5660 FIT samples to 
the laboratory. The median age of patients was 65 years 
(range: 2–99, IQR: 51–75) and 56.4% were female. One 
hundred and fifty-two of the samples (2.7%) were unsuit-
able for analysis (most commonly due to faecal contam-
ination) in whom 40 patients did not complete a repeat 
test. Ten patients had known IBD. In total, therefore, 50 
patients were excluded from further analysis leaving a 
cohort of 5372 patients of whom 1175 had f-Hb ≥10 µg/g 
(positivity: 21.9%) (figure 1). Of these, 2848 patients 
were referred immediately by their GP to secondary care, 
and three patients were admitted acutely. The positivity 
rate in referred patients was 37.0%. The number of FIT 
samples received per month increased over time, but 
positivity was relatively constant (figure 2). In this year 
under study a total of 4072 patients were investigated 
by the colorectal service (equating to an FIT test uptake 
of 70.5% in referred patients). The influence of the 
addition of f-Hb on clinical decision-making in patients 
presenting with new bowel symptoms is summarised in 
table 1.
Knowledge of the f-Hb had a significant effect on 
primary and secondary care clinical decision-making. 
Patients with f-Hb ≥10 µg/g were more likely to be 
referred to secondary care, where on triage to colo-
noscopy they were also more likely to be categorised as 
urgent/urgent suspected cancer than patients with f-Hb 
<10 µg/g. On the other hand, patients with f-Hb <10 
µg/g were less likely to be referred to secondary care, 
where on triage were more likely to be categorised to 
routine colonoscopy, or triaged to an outpatient clinic 
or a sigmoidoscopy than patients with f-Hb ≥10 µg/g. Of 
patients referred and triaged to colonoscopy, 55.0% had 
f-Hb ≥10 µg/g, whereas the majority of patients triaged to 
outpatient clinic or CT colonoscopy had f-Hb <10 µg/g. 
Seventy-one FIT samples were associated with a referral 
which was cancelled at the stage of vetting by the consul-
tant gastroenterologist, most frequently due to insuffi-
cient clinical information; 80.3% of these had f-Hb <10 
µg/g.
A total of 1447 patients ultimately completed full colo-
noscopy (table 2): 296 were found to have SBD (20.5%), 
comprising 95 CRC (6.6%), 133 HRA (9.2%) and 68 IBD 
(4.7%).
The prevalence of SBD detected at colonoscopy was 
associated with f-Hb measured at the point of referral; 
6.6% in patients with f-Hb <10 µg/g, compared with 32.3% 
in patients with f-Hb ≥10 µg/g (p<0.001). Two hundred 
and fifty-two of 296 cases of SBD (85.1%) were associated 
with f-Hb ≥10 µg/g. The prevalence of SBD was highest 
in patients with f-Hb ≥400 µg/g (54.0%), compared with 
24.2% in patients with f-Hb ≥10–399 µg/g.
Of the 44 patients with f-Hb, <10 µg/g found to have 
SBD at colonoscopy, there were 9 cases of CRC, 31 of 
HRA and 4 of IBD. Electronic patient record review of 
every individual who submitted an FIT sample but who 
did not have full colonic evaluation identified three 
further cases of CRC in patients with f-Hb <10 µg/g; all 
were admitted as emergencies with acute bowel obstruc-
tion within days of being referred and all had widespread 
metastatic disease on imaging (table 3). Of the eight 
patients who were fit enough for staging investigations, 
one was Dukes A and four were polyp cancers. Signifi-
cantly, 10 of the 12 cases of CRC had been referred either 
as ‘urgent’ or ‘urgent suspected cancer’ despite their 
f-Hb result, including seven with coexisting IDA.
Furthermore, 17 of the 31 patients with HRA were 
referred on the basis of coexisting IDA, diarrhoea, rectal 
bleeding, or a palpable lesion on rectal examination, and 
one of the four IBD cases had diarrhoea. In summary, 
using f-Hb as an adjunct to history, examination and full 
blood count resulted in the identification of 278 out of 
the 296 (93.9%) cases of SBD.
Eighty-three patients (2.9%) were triaged to CT colo-
noscopy. The majority had altered bowel habit as the 
principal symptom (76.6%) and the remainder reported 
weight loss, anaemia, or rectal bleeding. Sixty-three 
patients (75.0%) had f-Hb <10 µg/g, and the remainder 
had a median f-Hb of 29 µg/g (IQR: 12–50). 51.0% had 
diverticulosis, 33.0% had no abnormality detected. Only 
one case of SBD was found (1.0%, namely a CRC in a 
patient with f-Hb ≥10 µg/g). Eleven polyps were detected, 
but all were <10 mm.
Referral rates to secondary care over the study period 
were compared with the corresponding time interval in 
the previous years. This revealed a reduction in referrals 
to the colorectal service from 4303 to 3905 (9.2%) and 
a reduction to gastroenterology outpatient clinics from 
2796 to 2121 (24.1%), giving an overall referral reduc-
tion of 15.1% in the first year following the introduction 
of FIT.
Further subanalysis revealed that, at the vetting stage, 
242 patients had the urgency of their referral altered by 
copyright.
 o
n
 20 M
ay 2019 by guest. Protected by
http://bmjopengastro.bmj.com/
BM
J O
pen G
astroenterol: first published as 10.1136/bmjgast-2019-000293 on 4 May 2019. Downloaded from 
4 Mowat C, et al. BMJ Open Gastro 2019;6:e000293. doi:10.1136/bmjgast-2019-000293
Open access 
Figure 1 The impact of the addition of a faecal immunochemical test (FIT) for haemoglobin as an adjunct to clinical 
assessment on the pathway of patients presenting to primary care with new bowel symptoms. IBD, inflammatory bowel 
disease; OGD, oesophagogastroduodenoscopy.
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Figure 2 Number of faecal immunochemical test (FIT) specimens received per month and percentage with faecal 
haemoglobin concentration (f-Hb) ≥10 µg/g.
Table 1 Influence of faecal haemoglobin concentration (f-Hb) on clinical decision-making in patients (n, (%)) with new bowel 
symptoms (n=5372)
Total n
f-Hb <10 µg/g
n (%)
f-Hb ≥10 µg/g
n (%) P value†
Patients with valid f-Hb result 5372 4197 (78.1) 1175 (21.9)
Not referred by GP 2521 2403 (95.3) 118 (4.7) <0.001
Acute admission 3 1 (33.3) 2 (66.6)
Referred to secondary care and triaged 2848 1794 (63.0) 1054 (37.0) <0.001
Referral rejected 71 57 (80.3) 14 (19.7) <0.001
Colonoscopy 1381 621 (45.0) 760 (55.0) <0.001
      Routine 345 258 (74.8) 87 (25.2) <0.001
      Urgent 617 268 (43.4) 349 (56.6) 0.0011
       Urgent suspected cancer 419 95 (22.7) 324 (77.3) <0.001
Gastroenterology clinic 672 521 (77.5) 151 (22.5) <0.001
Sigmoidoscopy 462 373 (80.7) 89 (19.3) <0.001
Upper GI endoscopy only 138 127 (92.0) 11 (8.0) <0.001
CT colonoscopy 83 62 (74.7) 21 (25.3) <0.001
Other clinic* 41 33 (80.5) 8 (19.5) <0.001
*Other clinic encompasses referrals to general surgical (25), liver (8), pelvic floor (3), inflammatory bowel disease (IBD, 3), paediatrics (1) and 
genetics (1) clinics.
†χ2 test.
GI, gastrointestinal; GP, general practitioner.
the consultant gastroenterologist prior to colonic inves-
tigation: 166 referrals were upgraded on the basis of the 
f-Hb ≥10 µg/g in which the yield of SBD was 33.7% (17 
CRC, 14 IBD and 25 HRA). Forty-four patients had their 
referral downgraded based on f-Hb <10 µg/g from either 
‘urgent’ or ‘urgent suspected cancer’ to ‘routine’; only 
two of these patients had SBD (both HRA). Thirty-two 
patients who had f-Hb <10 µg/g were upgraded on the 
basis of symptoms and patient history only; three had HRA 
and one patient had IBD.
The electronic patient record review of the 2521 
FIT samples not associated with an immediate referral 
revealed 95.3% recorded f-Hb <10 µg/g. Median age 63 
years (IQR: 2–99), 57.8% female. Over a median follow-up 
period of 11 months (range: 0–18), 183 (7.2%) were 
subsequently referred to the colorectal service; 27 (1.1%) 
attended the primary care OOH service with ongoing 
symptoms, but were not referred; 23 patients (0.9%) were 
admitted acutely; 9 patients tested positive on participa-
tion in the Scottish Bowel Screening Programme; 5 were 
recalled for a CRC surveillance colonoscopy, and 4 were 
referred to paediatric clinics. In total, 124 patients ulti-
mately completed bowel investigations. There were 15 
cases of SBD subsequently diagnosed (incidence: 0.6%); 
4 cases of CRC (incidence: 0.2%), 5 cases of HRA and 
6 new cases of IBD. All four CRC cases were associated 
with an initial f-Hb <10 µg/g. One 88-year-old patient 
with a progressive normocytic anaemia on rivaroxaban 
was referred 10 months later after a repeat FIT recorded 
f-Hb ≥400 µg/g: investigations revealed a Dukes C 
sigmoid cancer and locally advanced prostate cancer. 
Another patient who initially presented with abdominal 
pain was admitted 12 months later with obstructive symp-
toms with CT revealing a Dukes C CRC at the splenic 
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Table 2 Prevalence of significant bowel disease (n; %) present at colonoscopy (colorectal cancer (CRC), higher risk adenoma 
(HRA), inflammatory bowel disease (IBD)), by category of faecal haemoglobin concentration (f-Hb) measured in primary care 
(n=1447)
Colonoscopy completed
(n=1447)
<10 µg/g 
(n=667)
≥10 µg/g 
(n=780) P value†
Colorectal cancer 95 (6.6) 9 (1.3) 86 (11.0) <0.001
Higher risk adenoma 133 (9.2) 31 (4.6) 102 (13.1) <0.001
Inflammatory bowel disease 68 (4.7) 4 (0.6) 64 (8.2) 0.003
CRC+HRA+IBD 296 (20.5) 44 (6.6) 252 (32.3) <0.001
Other* 615 (42.5) 304 (45.6) 311 (39.9) 0.038
No pathology 536 (37.0) 319 (47.8) 217 (27.8) <0.001
*Low-risk adenoma, hyperplastic polyps, diverticular disease, angiodysplasia, haemorrhoids, microscopic colitis, radiation proctitis, and 
solitary rectal ulcer.
†χ2 test.
Table 3 Cases of colorectal cancer presenting in patients with f-Hb <10 µg/g but who had been referred from primary care 
on clinical judgement (n=12)
Urgency of 
referral Age Gender Symptoms Hb (g/L)
Tumour 
size (mm) Tumour site
Dukes 
stage
USC 78 M IDA, altered bowel habit 120 26 Descending A
Urgent 87 F IDA 108 28 Caecum Polyp 
cancer
Urgent 74 F IDA 102 60 Caecum N/A
Urgent 66 M IDA, weight loss 94 57 Transverse B
Routine 76 F Alternating diarrhoea/
constipation
132 13 Caecum Polyp 
cancer
Urgent 76 M Abdominal pain, 
constipation
138 22 Sigmoid C2
Routine 58 M Rectal bleeding 134 8 Descending Polyp 
cancer
Urgent 54 F IDA 65 30 Transverse B
USC 89 M IDA 71 17 Transverse Polyp 
cancer
USC 84 F IDA, weight loss 98 N/A Caecum N/A
Urgent 67 M Alternating diarrhoea/
constipation, abdominal 
pain, weight loss
134 N/A Transverse N/A
USC 60 F Alternating diarrhoea/
constipation
139 N/A Transverse N/A
IDA, iron deficiency anaemia; N/A, not applicable; USC, urgent suspected cancer.
flexure. Another with diarrhoea was admitted 6 weeks 
later with a palpable mass and a CT scan showed meta-
static bowel cancer. The fourth patient was referred to 
the haematology clinic shortly after completion of the 
FIT on the basis of pelvic pain, hypercalcaemia, and a 
lytic bone lesion on pelvic X-ray. The patient was diag-
nosed with multiple myeloma and rectal cancer based on 
CT scan imaging alone as no histology was obtained prior 
to death.
Post hoc anonymised record linkage to the Scottish 
Cancer Registry using the CHI number of all patients who 
have submitted a FIT test to the laboratory generated a 
list of all incident cases of CRC since introduction of the 
FIT test. The most recent recorded registration of CRC 
was in November 2018. Confining the analysis to FIT test 
results recorded in the first year of the service generated 
a list of 103 incident cases of CRC with ICD 10 codes 
C18, C19, and C20 over a follow-up period between 23 
and 35 months. All patients diagnosed with CRC were 
residents in the NHS Tayside catchment area. In other 
words, no additional cases of cancer were detected within 
the cohort described, over and above those identified by 
manual case note review.
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dIscussIon
To our knowledge, this is the first report to describe the 
utility of providing FIT in primary care as a routine service 
to assist in the assessment of patients presenting with new 
bowel symptoms. In the first year, over 5600 samples were 
received in the laboratory with a positivity of 21.6% at 
the evidence-based recommended cut-off of ≥10 µg/g.20 
Almost 50% of samples were associated with no imme-
diate referral to secondary care (of which 95.0% had f-Hb 
<10 µg/g). Referral rates to secondary care simultane-
ously reduced by 15.1%. Of those patients referred and 
investigated, we confirmed that f-Hb <10 µg/g alone was 
a good rule-out test for SBD and, if used in conjunction 
with full blood count and clinical assessment, 93.9% of 
all SBD would have been correctly identified. We noted 
that the yield of SBD in those patients triaged to colo-
noscopy increased from 13.9% to 20.5%, suggesting that 
patients were more appropriately targeted for colonos-
copy. Further, the subsequent incidence of SBD in those 
patients not immediately referred was very low at 0.7%. 
Ninety-nine (96%) of the 103 incident CRC cases were 
correctly identified with this strategy. Post hoc anonymised 
record linkage to the Scottish Cancer Registry identified 
no additional incident cases of CRC within the study 
cohort up to 35 months later and provides all clinicians 
with the necessary reassurance.
The strength of our data is that they were obtained from 
a single NHS Board in which all referrals from primary 
care enter through a common referral pathway, removing 
selection bias. Furthermore, patients were encouraged to 
complete an FIT irrespective of their presenting bowel 
symptoms. FIT samples were delivered to the laboratory 
via a daily delivery service and analyses performed every 
weekday. All patient data including referral symptoms, 
laboratory results, colonoscopy findings and admission 
notes are linked via their CHI number and, therefore, 
all outcome data were available. Importantly, we supple-
mented a manual case note review with a post hoc record 
linkage of all patients with an FIT test result to the 
Scottish Cancer Registry to identify any missed cases. A 
limitation is that we could neither capture the number 
of patients who were asked to complete an FIT test but 
chose not to, nor the number of further attendances to 
primary care of those patients who were not immediately 
referred and, thus, the true number of further contacts 
may be an underestimate.
Over the course of 1 year, we provided Gps and consul-
tant gastroenterologists with supporting information (via 
newsletters and a link to the Gastroenterology website) 
on the importance of testing for f-Hb and the significance 
of a finding of f-Hb <10 µg/g, and this was assisted by a 
robust electronic test requesting and reporting system, 
and interim data analyses on the impact of the new 
service. Within 6 months of making FIT available, around 
two-thirds of all referrals to secondary care submitted FIT 
samples. The uptake of FIT in this symptomatic popu-
lation proved better than the uptake of gFOBT in the 
Scottish Bowel Screening Programme in our region,22 
suggesting good patient acceptability. Knowledge of f-Hb 
was of benefit to the gastroenterologists. Over the first 
year, it became clear there was an association between 
f-Hb and the prevalence of SBD detected at colonoscopy; 
6.6% in patients with f-Hb <10 µg/g, 32.0% in all patients 
with f-Hb ≥10 µg/g, rising to 53.8% in patients with f-Hb 
≥400 µg/g. It has previously been reported that f-Hb is 
directly related to the severity of underlying colorectal 
disease.23 At vetting, the urgency of investigation was 
adjusted in 210 referrals on the basis of f-Hb with clear 
benefits to these patients.
However, no test is perfect. As indicated by the negative 
predictive value, it is inevitable that some patients with 
f-Hb <10 µg/g will have underlying SBD. Of the patients 
referred with f-Hb <10 µg/g, 12 had CRC, but all had 
been referred on the basis of IDA, rectal bleeding, or clin-
ical acumen—thus emphasising the thesis that FIT is an 
adjunct to current approaches for assessment and is not 
a diagnostic test on its own.24 Of the patients with f-Hb 
<10 µg/g who were not immediately referred, four were 
subsequently recorded to have CRC. However, these data 
have to be placed in context. Colonoscopy is considered 
as the gold standard test, but is associated with an interval 
cancer rate of 0.6% in patients under surveillance25 and 
a miss rate of 11.0% for advanced adenomas and up to 
26% for all adenomas.26 27
In summary, we have demonstrated that FIT can be 
introduced into primary care as an adjunct to history, 
examination and blood tests in the assessment of patients 
with new bowel symptoms. The challenges and consider-
ations required to set up such a service have recently been 
reviewed.28 Using a cut-off of f-Hb <10 µg/g, in the absence 
of red flag features of IDA, persistent diarrhoea, rectal 
bleeding, or palpable mass, provides an objective means 
of identifying patients with an extremely low risk of under-
lying SBD and thus avoids invasive investigation. Using 
this strategy, we have demonstrated that the referral rate 
to secondary care has decreased and that colonoscopy is 
more appropriately targeted. Furthermore, our approach 
demonstrates that knowledge of f-Hb, in conjunction with 
clinical assessment and full blood count, enables an objec-
tive assessment of a patient’s risk of underlying SBD which 
surpasses the predictive value of symptoms alone. These 
new data imply that FIT is of great value in the assessment of 
all patients presenting with new bowel symptoms and there-
fore should not be reserved simply for perceived ‘low-risk’ 
patients as currently suggested.29 Future research should 
focus on refining the predictive value of an elevated f-Hb, 
and on whether FIT could be used as a ‘rule-out’ test in any 
other patient groups referred for colonoscopy. Moreover, 
it might be that other approaches, including risk scoring 
using additional variables to the f-Hb, such as the Faecal 
Haemoglobin Concentration, Age and Sex Test score, 
have advantages in this clinical setting30: further research 
is required.
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